Umbilical cord-derived mesenchymal stromal cells for COVID-19 ARDS: a phase 1 case series
Clinical Infection in Practice · 2026-11 · 100744
DOI: 10.1016/j.clinpr.2026.100744 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infection in Practice, 2026-11. Verfasst von Kazuaki Fukushima und 8 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Background
Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) carried high mortality before vaccines became available, and options for patients who deteriorate despite corticosteroids and antivirals are limited. Umbilical cord-derived mesenchymal stromal cells (UC-MSCs) have anti-inflammatory and tissue-reparative properties. HLC-001 is a cryopreserved, serum-free manufactured allogeneic UC-MSC product. We report the first patients treated with HLC-001 for COVID-19 ARDS. Case report In an open-label, single-arm, single-centre phase 1 trial using a 3 + 3 design, three unvaccinated Japanese men aged 65, 79 and 81 years with COVID-19 ARDS by the Berlin definition that had not improved on standard care received HLC-001 2.0 × 10 6 cells/kg intravenously twice weekly for two cycles (four infusions). None was intubated at enrolment; all received remdesivir and systemic corticosteroids. The primary endpoint was dose-limiting toxicity (DLT) up to 28 days after the last infusion.
Results
No DLT occurred and the starting dose was considered tolerable. Eighteen adverse events were recorded in the three patients; none was attributed to HLC-001 by the investigator or the Data Safety Monitoring Board, and no grade 4 or 5 event, serious adverse event or death occurred. Two grade 3 events, alanine aminotransferase elevation and creatine kinase elevation, were attributed to concomitant medication (corticosteroid, with a possible contribution of trimethoprim/sulfamethoxazole to the alanine aminotransferase elevation) and resolved. No patient required mechanical ventilation, all were weaned from supplemental oxygen, and SARS-CoV-2 PCR was negative at the final on-study assessment in all three.
Conclusion
HLC-001 at 2.0 × 10 6 cells/kg was tolerated in three non-intubated patients with COVID-19 ARDS. An uncontrolled series of this size cannot assess efficacy, and the observed clinical course is hypothesis-generating only. This study was registered with the Japan Registry of Clinical Trials (jRCT1080225369).
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Fukushima, K., Harata, M., Nagamura-Inoue, T., Nagamura, F., Takizawa, A., Jung, S., Tanaka, M., Sekiya, N., & Imamura, A. (2026). Umbilical cord-derived mesenchymal stromal cells for COVID-19 ARDS: a phase 1 case series. Clinical Infection in Practice, 100744. https://doi.org/10.1016/j.clinpr.2026.100744
Vancouver
Fukushima K, Harata M, Nagamura-Inoue T, Nagamura F, Takizawa A, Jung S, et al. Umbilical cord-derived mesenchymal stromal cells for COVID-19 ARDS: a phase 1 case series. Clinical Infection in Practice. 2026:100744. doi:10.1016/j.clinpr.2026.100744
BibTeX
@article{Fukushima2026,
author = {Fukushima, Kazuaki and Harata, Masamitsu and Nagamura-Inoue, Tokiko and Nagamura, Fumitaka and Takizawa, Ayumi and Jung, Seowoong and Tanaka, Masaru and Sekiya, Noritaka and Imamura, Akifumi},
title = {Umbilical cord-derived mesenchymal stromal cells for COVID-19 ARDS: a phase 1 case series},
journal = {Clinical Infection in Practice},
year = {2026},
pages = {100744},
doi = {10.1016/j.clinpr.2026.100744}
}
EUVIMED